Clinical Trial Update: Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)

View source ↗

Summary

A completed clinical trial evaluated the addition of 20 mg/day zeaxanthin to a triple-therapy regimen for exudative age-related macular degeneration. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exudative Age-related Macular Degeneration

Drugs mentioned

• Zeaxanthin (Zeaxanthin)

Snippet

Sponsor: The Retina Center of St. Louis County, PC | Conditions: Exudative Age-Related Macular Degeneration | Status: COMPLETED